Company intelligence / Profile preview

Ablacon

Wheat Ridge, Colorado, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Ablacon has developed an artificial intelligence-powered mapping system that visualizes and analyzes the flow of electrical activity within the heart to identify sources and drivers of atrial fibrillation. The system, which received CE Mark in 2018 and FDA 510(k) clearance as OptiMap, is used to guide targeted catheter ablation therapy. Early clinical experience indicates promise for improving outcomes in AFib treatment[3][4].

Therapeutic areas: Cardiovascular
Modalities: DeviceArtificial intelligence-enabled mapping system (Device)
Industry: Medical Imaging

Partnerships

Cortex (integrated mapping/ablation solution suite partnership; Cortex will use Ablacon’s EGF technology)[2]Ajax Health (lead investor/incubator relationship)[3]

Beyond the preview

Go deeper on Ablacon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ablacon.

Explore the full profile